Clinical Trial Update: A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) [Phase 2]

View source ↗

Summary

Phase 2 trial update for TQ-B3101 in relapsed or refractory anaplastic large cell lymphoma (ALCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Drugs mentioned

• TQ-B3101 (TQ-B3101)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL) | Phase 2 | Status: UNKNOWN